Rep. Julie Johnson Sells Zoetis Inc. (NYSE:ZTS) Stock

Representative Julie Johnson (D-Texas) recently sold shares of Zoetis Inc. (NYSE:ZTS). In a filing disclosed on April 14th, the Representative disclosed that they had sold between $1,001 and $15,000 in Zoetis stock on March 3rd. The trade occurred in the Representative’s “MERRILL LYNCH LONG TERM GROWTH” account.

Representative Julie Johnson also recently made the following trade(s):

• Purchased $1,001 – $15,000 in shares of Capital One Financial (NYSE:COF) on 3/21/2025.
• Sold $1,001 – $15,000 in shares of Accenture (NYSE:ACN) on 3/19/2025.
• Purchased $1,001 – $15,000 in shares of The Cigna Group (NYSE:CI) on 3/19/2025.
• Sold $1,001 – $15,000 in shares of Accenture (NYSE:ACN) on 3/14/2025.
• Sold $1,001 – $15,000 in shares of Accenture (NYSE:ACN) on 3/12/2025.
• Purchased $1,001 – $15,000 in shares of 3M (NYSE:MMM) on 3/12/2025.
• Sold $1,001 – $15,000 in shares of Webster Financial (NYSE:WBS) on 3/11/2025.
• Sold $1,001 – $15,000 in shares of Sonos (NASDAQ:SONO) on 3/11/2025.
• Sold $1,001 – $15,000 in shares of Taiwan Semiconductor Manufacturing (NYSE:TSM) on 3/11/2025.
• Sold $1,001 – $15,000 in shares of Teradyne (NASDAQ:TER) on 3/3/2025.

Zoetis Stock Up 1.3 %

NYSE:ZTS traded up $1.88 during mid-day trading on Thursday, hitting $148.64. 4,239,783 shares of the company’s stock traded hands, compared to its average volume of 2,564,057. Zoetis Inc. has a twelve month low of $139.70 and a twelve month high of $200.33. The company has a market capitalization of $66.32 billion, a P/E ratio of 27.17, a P/E/G ratio of 2.78 and a beta of 0.92. The company has a debt-to-equity ratio of 1.09, a quick ratio of 1.08 and a current ratio of 1.75. The company has a fifty day moving average of $161.02 and a 200 day moving average of $170.60.

Zoetis (NYSE:ZTS) last announced its quarterly earnings data on Thursday, February 13th. The company reported $1.40 earnings per share for the quarter, beating analysts’ consensus estimates of $1.37 by $0.03. Zoetis had a net margin of 26.86% and a return on equity of 53.82%. The firm had revenue of $2.32 billion for the quarter, compared to analyst estimates of $2.30 billion. On average, analysts forecast that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, June 3rd. Stockholders of record on Monday, April 21st will be given a dividend of $0.50 per share. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.35%. The ex-dividend date of this dividend is Monday, April 21st. Zoetis’s payout ratio is presently 36.56%.

Analysts Set New Price Targets

A number of analysts have recently commented on ZTS shares. Morgan Stanley lowered their target price on Zoetis from $243.00 to $238.00 and set an “overweight” rating on the stock in a research note on Friday, February 14th. Stifel Nicolaus cut their target price on shares of Zoetis from $180.00 to $165.00 and set a “buy” rating for the company in a research note on Monday. StockNews.com raised shares of Zoetis from a “hold” rating to a “buy” rating in a research note on Friday, March 7th. Barclays lifted their price target on Zoetis from $242.00 to $244.00 and gave the stock an “overweight” rating in a research note on Friday, February 14th. Finally, Piper Sandler lifted their target price on shares of Zoetis from $200.00 to $205.00 and gave the stock an “overweight” rating in a research note on Thursday, February 27th. One analyst has rated the stock with a hold rating, ten have issued a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, Zoetis has an average rating of “Buy” and a consensus target price of $214.40.

Insiders Place Their Bets

In other Zoetis news, Director Willie M. Reed sold 1,210 shares of the firm’s stock in a transaction that occurred on Tuesday, March 11th. The shares were sold at an average price of $166.14, for a total value of $201,029.40. Following the sale, the director now owns 11,245 shares in the company, valued at approximately $1,868,244.30. This trade represents a 9.71 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Roxanne Lagano sold 326 shares of the company’s stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $170.00, for a total transaction of $55,420.00. Following the completion of the sale, the executive vice president now directly owns 15,781 shares of the company’s stock, valued at $2,682,770. The trade was a 2.02 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 1,862 shares of company stock valued at $312,254 over the last quarter. Insiders own 0.16% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the business. Howard Capital Management Group LLC raised its position in shares of Zoetis by 0.8% in the 3rd quarter. Howard Capital Management Group LLC now owns 104,866 shares of the company’s stock worth $20,489,000 after buying an additional 883 shares during the period. Principal Financial Group Inc. boosted its stake in shares of Zoetis by 17.3% during the 3rd quarter. Principal Financial Group Inc. now owns 2,377,403 shares of the company’s stock valued at $464,497,000 after buying an additional 351,372 shares during the last quarter. Diamant Asset Management Inc. increased its position in shares of Zoetis by 2.4% in the 3rd quarter. Diamant Asset Management Inc. now owns 4,465 shares of the company’s stock worth $872,000 after purchasing an additional 105 shares during the last quarter. World Investment Advisors LLC lifted its holdings in Zoetis by 29.1% during the 3rd quarter. World Investment Advisors LLC now owns 34,236 shares of the company’s stock worth $6,689,000 after buying an additional 7,709 shares during the last quarter. Finally, Wilmington Savings Fund Society FSB increased its stake in Zoetis by 801.0% during the third quarter. Wilmington Savings Fund Society FSB now owns 18,606 shares of the company’s stock valued at $3,635,000 after purchasing an additional 16,541 shares during the last quarter. Hedge funds and other institutional investors own 92.80% of the company’s stock.

About Representative Johnson

Julie Johnson (Democratic Party) is a member of the U.S. House, representing Texas’ 32nd Congressional District. She assumed office on January 3, 2025. Her current term ends on January 3, 2027.

Johnson (Democratic Party) ran for election to the U.S. House to represent Texas’ 32nd Congressional District. She won in the general election on November 5, 2024.

Julie Johnson earned a B.A. in history and government from the University of Texas at Austin in 1987 and a J.D. from the University of Houston Law Center in 1991. Johnson’s career experience includes working as an attorney.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.